Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF – Get Free Report)’s stock price fell 11% during mid-day trading on Thursday . The company traded as low as $9.45 and last traded at $9.45. 400 shares traded hands during trading, a decline of 76% from the average session volume of 1,652 shares. The stock had previously closed at $10.62.
Nxera Pharma Stock Performance
The stock has a 50-day moving average of $9.90 and a 200-day moving average of $9.83.
Nxera Pharma Company Profile
Nxera Pharma Co, Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications.
See Also
- Five stocks we like better than Nxera Pharma
- What is a Bond Market Holiday? How to Invest and Trade
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Why Dell Can Continue Winning in AI and Beyond
- P/E Ratio Calculation: How to Assess Stocks
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Nxera Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nxera Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
